Skip to main content
Erschienen in: Annals of Hematology 1/2015

01.01.2015 | Original Article

High APRIL but not BAFF serum levels are associated with poor outcome in patients with follicular lymphoma

verfasst von: Ya-Jun Li, Zhi-Ming Li, Zhong-Jun Xia, Su Li, Yi Xia, Hui-Qiang Huang, Jia-Jia Huang, Ping-Yong Yi, Wen-Qi Jiang

Erschienen in: Annals of Hematology | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Elevated B cell activation factor (BAFF) and a proliferation-inducing ligand (APRIL) serum levels have been reported to correlate with worse prognosis in B cell-derived malignancies. However, limited information exists regarding the prognostic significance of BAFF and APRIL serum levels in follicular lymphoma (FL). We measured BAFF and APRIL serum levels for 81 patients with newly diagnosed FL and 12 healthy controls. The mean ± standard deviation (SD) BAFF serum level (1,193.86 ± 1,126.51 pg/ml) was higher in patients with FL than that in the controls (477.16 ± 155.55 pg/ml; P < 0.001). No significant difference in the mean ± SD serum level of APRIL was found between patients and healthy controls (14.39 ± 43.33 vs 5.07 ± 2.52 ng/ml; P = 0.193). When the patients were divided into low- and high-BAFF and low- and high-APRIL groups based on the median value of the BAFF and APRIL serum levels (855.14 pg/ml and 6.35 ng/ml, respectively), a high APRIL, but not a high BAFF, serum level significantly correlated with low complete response rate to initial therapy, high relapse/progression rate, and inferior progression-free survival (PFS; P = 0.019) and overall survival (OS; P = 0.008) rates. A high APRIL serum level was also significantly associated with decreased PFS and OS in patients treated with non-rituximab regimens but not in patients treated with rituximab-containing regimens. The APRIL serum level remained an independent predictor for PFS and OS in multivariate analysis. APRIL may be an important prognostic predictor with potential significance as a therapeutic target in FL.
Literatur
1.
Zurück zum Zitat Armitage JO, Weisenburger DD (1998) New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Project. J Clin Oncol 16(8):2780–2795PubMed Armitage JO, Weisenburger DD (1998) New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Project. J Clin Oncol 16(8):2780–2795PubMed
2.
Zurück zum Zitat Biagi JJ, Seymour JF (2002) Insights into the molecular pathogenesis of follicular lymphoma arising from analysis of geographic variation. Blood 99(12):4265–4275PubMedCrossRef Biagi JJ, Seymour JF (2002) Insights into the molecular pathogenesis of follicular lymphoma arising from analysis of geographic variation. Blood 99(12):4265–4275PubMedCrossRef
3.
Zurück zum Zitat Ghielmini M (2010) Follicular lymphoma. Ann Oncol 21(Suppl 7):vii151–vii153PubMed Ghielmini M (2010) Follicular lymphoma. Ann Oncol 21(Suppl 7):vii151–vii153PubMed
4.
Zurück zum Zitat Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, Au WY, Bellei M, Brice P, Caballero D, Coiffier B, Conde-Garcia E, Doyen C, Federico M, Fisher RI, Garcia-Conde JF, Guglielmi C, Hagenbeek A, Haioun C, LeBlanc M, Lister AT, Lopez-Guillermo A, McLaughlin P, Milpied N, Morel P, Mounier N, Proctor SJ, Rohatiner A, Smith P, Soubeyran P, Tilly H, Vitolo U, Zinzani PL, Zucca E, Montserrat E (2004) Follicular lymphoma international prognostic index. Blood 104(5):1258–1265PubMedCrossRef Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, Au WY, Bellei M, Brice P, Caballero D, Coiffier B, Conde-Garcia E, Doyen C, Federico M, Fisher RI, Garcia-Conde JF, Guglielmi C, Hagenbeek A, Haioun C, LeBlanc M, Lister AT, Lopez-Guillermo A, McLaughlin P, Milpied N, Morel P, Mounier N, Proctor SJ, Rohatiner A, Smith P, Soubeyran P, Tilly H, Vitolo U, Zinzani PL, Zucca E, Montserrat E (2004) Follicular lymphoma international prognostic index. Blood 104(5):1258–1265PubMedCrossRef
5.
Zurück zum Zitat Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, Pro B, Pileri S, Pulsoni A, Soubeyran P, Cortelazzo S, Martinelli G, Martelli M, Rigacci L, Arcaini L, Di Raimondo F, Merli F, Sabattini E, McLaughlin P, Solal-Celigny P (2009) Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 27(27):4555–4562PubMedCrossRef Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, Pro B, Pileri S, Pulsoni A, Soubeyran P, Cortelazzo S, Martinelli G, Martelli M, Rigacci L, Arcaini L, Di Raimondo F, Merli F, Sabattini E, McLaughlin P, Solal-Celigny P (2009) Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 27(27):4555–4562PubMedCrossRef
6.
Zurück zum Zitat Moore PA, Belvedere O, Orr A, Pieri K, LaFleur DW, Feng P, Soppet D, Charters M, Gentz R, Parmelee D, Li Y, Galperina O, Giri J, Roschke V, Nardelli B, Carrell J, Sosnovtseva S, Greenfield W, Ruben SM, Olsen HS, Fikes J, Hilbert DM (1999) BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 285(5425):260–263PubMedCrossRef Moore PA, Belvedere O, Orr A, Pieri K, LaFleur DW, Feng P, Soppet D, Charters M, Gentz R, Parmelee D, Li Y, Galperina O, Giri J, Roschke V, Nardelli B, Carrell J, Sosnovtseva S, Greenfield W, Ruben SM, Olsen HS, Fikes J, Hilbert DM (1999) BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 285(5425):260–263PubMedCrossRef
7.
Zurück zum Zitat Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N, Ambrose C, Lawton P, Bixler S, Acha-Orbea H, Valmori D, Romero P, Werner-Favre C, Zubler RH, Browning JL, Tschopp J (1999) BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 189(11):1747–1756PubMedCentralPubMedCrossRef Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N, Ambrose C, Lawton P, Bixler S, Acha-Orbea H, Valmori D, Romero P, Werner-Favre C, Zubler RH, Browning JL, Tschopp J (1999) BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 189(11):1747–1756PubMedCentralPubMedCrossRef
8.
Zurück zum Zitat Gross JA, Johnston J, Mudri S, Enselman R, Dillon SR, Madden K, Xu W, Parrish-Novak J, Foster D, Lofton-Day C, Moore M, Littau A, Grossman A, Haugen H, Foley K, Blumberg H, Harrison K, Kindsvogel W, Clegg CH (2000) TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404(6781):995–999PubMedCrossRef Gross JA, Johnston J, Mudri S, Enselman R, Dillon SR, Madden K, Xu W, Parrish-Novak J, Foster D, Lofton-Day C, Moore M, Littau A, Grossman A, Haugen H, Foley K, Blumberg H, Harrison K, Kindsvogel W, Clegg CH (2000) TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404(6781):995–999PubMedCrossRef
9.
Zurück zum Zitat Thompson JS, Bixler SA, Qian F, Vora K, Scott ML, Cachero TG, Hession C, Schneider P, Sizing ID, Mullen C, Strauch K, Zafari M, Benjamin CD, Tschopp J, Browning JL, Ambrose C (2001) BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 293(5537):2108–2111PubMedCrossRef Thompson JS, Bixler SA, Qian F, Vora K, Scott ML, Cachero TG, Hession C, Schneider P, Sizing ID, Mullen C, Strauch K, Zafari M, Benjamin CD, Tschopp J, Browning JL, Ambrose C (2001) BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 293(5537):2108–2111PubMedCrossRef
10.
Zurück zum Zitat Novak AJ, Bram RJ, Kay NE, Jelinek DF (2002) Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival. Blood 100(8):2973–2979PubMedCrossRef Novak AJ, Bram RJ, Kay NE, Jelinek DF (2002) Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival. Blood 100(8):2973–2979PubMedCrossRef
11.
Zurück zum Zitat He B, Chadburn A, Jou E, Schattner EJ, Knowles DM, Cerutti A (2004) Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL. J Immunol 172(5):3268–3279PubMedCrossRef He B, Chadburn A, Jou E, Schattner EJ, Knowles DM, Cerutti A (2004) Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL. J Immunol 172(5):3268–3279PubMedCrossRef
12.
Zurück zum Zitat Kern C, Cornuel JF, Billard C, Tang R, Rouillard D, Stenou V, Defrance T, Ajchenbaum-Cymbalista F, Simonin PY, Feldblum S, Kolb JP (2004) Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood 103(2):679–688PubMedCrossRef Kern C, Cornuel JF, Billard C, Tang R, Rouillard D, Stenou V, Defrance T, Ajchenbaum-Cymbalista F, Simonin PY, Feldblum S, Kolb JP (2004) Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood 103(2):679–688PubMedCrossRef
13.
Zurück zum Zitat Tangye SG, Bryant VL, Cuss AK, Good KL (2006) BAFF, APRIL and human B cell disorders. Semin Immunol 18(5):305–317PubMedCrossRef Tangye SG, Bryant VL, Cuss AK, Good KL (2006) BAFF, APRIL and human B cell disorders. Semin Immunol 18(5):305–317PubMedCrossRef
14.
Zurück zum Zitat Hahne M, Kataoka T, Schroter M, Hofmann K, Irmler M, Bodmer JL, Schneider P, Bornand T, Holler N, French LE, Sordat B, Rimoldi D, Tschopp J (1998) APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med 188(6):1185–1190PubMedCentralPubMedCrossRef Hahne M, Kataoka T, Schroter M, Hofmann K, Irmler M, Bodmer JL, Schneider P, Bornand T, Holler N, French LE, Sordat B, Rimoldi D, Tschopp J (1998) APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med 188(6):1185–1190PubMedCentralPubMedCrossRef
15.
Zurück zum Zitat Novak AJ, Grote DM, Stenson M, Ziesmer SC, Witzig TE, Habermann TM, Harder B, Ristow KM, Bram RJ, Jelinek DF, Gross JA, Ansell SM (2004) Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. Blood 104(8):2247–2253PubMedCrossRef Novak AJ, Grote DM, Stenson M, Ziesmer SC, Witzig TE, Habermann TM, Harder B, Ristow KM, Bram RJ, Jelinek DF, Gross JA, Ansell SM (2004) Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. Blood 104(8):2247–2253PubMedCrossRef
16.
Zurück zum Zitat Oki Y, Georgakis GV, Migone TS, Kwak LW, Younes A (2007) Prognostic significance of serum B-lymphocyte stimulator in Hodgkin’s lymphoma. Haematologica 92(2):269–270PubMedCrossRef Oki Y, Georgakis GV, Migone TS, Kwak LW, Younes A (2007) Prognostic significance of serum B-lymphocyte stimulator in Hodgkin’s lymphoma. Haematologica 92(2):269–270PubMedCrossRef
17.
Zurück zum Zitat Planelles L, Castillo-Gutierrez S, Medema JP, Morales-Luque A, Merle-Beral H, Hahne M (2007) APRIL but not BLyS serum levels are increased in chronic lymphocytic leukemia: prognostic relevance of APRIL for survival. Haematologica 92(9):1284–1285PubMedCrossRef Planelles L, Castillo-Gutierrez S, Medema JP, Morales-Luque A, Merle-Beral H, Hahne M (2007) APRIL but not BLyS serum levels are increased in chronic lymphocytic leukemia: prognostic relevance of APRIL for survival. Haematologica 92(9):1284–1285PubMedCrossRef
18.
Zurück zum Zitat Tecchio C, Nadali G, Scapini P, Bonetto C, Visco C, Tamassia N, Vassilakopoulos TP, Pangalis GA, Calzetti F, Nardelli B, Roschke V, Gottardi M, Zampieri F, Gherlinzoni F, Facchetti F, Pizzolo G, Cassatella MA (2007) High serum levels of B-lymphocyte stimulator are associated with clinical-pathological features and outcome in classical Hodgkin lymphoma. Br J Haematol 137(6):553–559PubMedCrossRef Tecchio C, Nadali G, Scapini P, Bonetto C, Visco C, Tamassia N, Vassilakopoulos TP, Pangalis GA, Calzetti F, Nardelli B, Roschke V, Gottardi M, Zampieri F, Gherlinzoni F, Facchetti F, Pizzolo G, Cassatella MA (2007) High serum levels of B-lymphocyte stimulator are associated with clinical-pathological features and outcome in classical Hodgkin lymphoma. Br J Haematol 137(6):553–559PubMedCrossRef
19.
Zurück zum Zitat Kim SJ, Lee SJ, Choi IY, Park Y, Choi CW, Kim IS, Yu W, Hwang HS, Kim BS (2008) Serum BAFF predicts prognosis better than APRIL in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP chemotherapy. Eur J Haematol 81(3):177–184PubMedCrossRef Kim SJ, Lee SJ, Choi IY, Park Y, Choi CW, Kim IS, Yu W, Hwang HS, Kim BS (2008) Serum BAFF predicts prognosis better than APRIL in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP chemotherapy. Eur J Haematol 81(3):177–184PubMedCrossRef
20.
Zurück zum Zitat Ansell SM, Novak AJ, Ziesmer S, Price-Troska T, LaPlant B, Dillon SR, Witzig TE (2009) Serum BLyS levels increase after rituximab as initial therapy in patients with follicular grade 1 non-Hodgkin lymphoma. Am J Hematol 84(2):71–73PubMedCentralPubMedCrossRef Ansell SM, Novak AJ, Ziesmer S, Price-Troska T, LaPlant B, Dillon SR, Witzig TE (2009) Serum BLyS levels increase after rituximab as initial therapy in patients with follicular grade 1 non-Hodgkin lymphoma. Am J Hematol 84(2):71–73PubMedCentralPubMedCrossRef
21.
Zurück zum Zitat Moreaux J, Legouffe E, Jourdan E, Quittet P, Reme T, Lugagne C, Moine P, Rossi JF, Klein B, Tarte K (2004) BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 103(8):3148–3157PubMedCentralPubMedCrossRef Moreaux J, Legouffe E, Jourdan E, Quittet P, Reme T, Lugagne C, Moine P, Rossi JF, Klein B, Tarte K (2004) BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 103(8):3148–3157PubMedCentralPubMedCrossRef
22.
Zurück zum Zitat Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (2008) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. International Agency for Research on Cancer, Lyon, France Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (2008) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. International Agency for Research on Cancer, Lyon, France
23.
Zurück zum Zitat Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17(4):1244PubMed Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17(4):1244PubMed
24.
Zurück zum Zitat Briones J, Timmerman JM, Hilbert DM, Levy R (2002) BLyS and BLyS receptor expression in non-Hodgkin’s lymphoma. Exp Hematol 30(2):135–141PubMedCrossRef Briones J, Timmerman JM, Hilbert DM, Levy R (2002) BLyS and BLyS receptor expression in non-Hodgkin’s lymphoma. Exp Hematol 30(2):135–141PubMedCrossRef
25.
Zurück zum Zitat Oki Y, Georgakis GV, Migone TS, Kwak LW, Younes A (2007) Elevated serum BLyS levels in patients with non-Hodgkin lymphoma. Leuk Lymphoma 48(9):1869–1871PubMedCrossRef Oki Y, Georgakis GV, Migone TS, Kwak LW, Younes A (2007) Elevated serum BLyS levels in patients with non-Hodgkin lymphoma. Leuk Lymphoma 48(9):1869–1871PubMedCrossRef
26.
Zurück zum Zitat Novak AJ, Grote DM, Ziesmer SC, Kline MP, Manske MK, Slager S, Witzig TE, Shanafelt T, Call TG, Kay NE, Jelinek DF, Cerhan JR, Gross JA, Harder B, Dillon SR, Ansell SM (2006) Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disorders. J Clin Oncol 24(6):983–987PubMedCrossRef Novak AJ, Grote DM, Ziesmer SC, Kline MP, Manske MK, Slager S, Witzig TE, Shanafelt T, Call TG, Kay NE, Jelinek DF, Cerhan JR, Gross JA, Harder B, Dillon SR, Ansell SM (2006) Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disorders. J Clin Oncol 24(6):983–987PubMedCrossRef
27.
Zurück zum Zitat Molica S, Digiesi G, Mauro F, Mirabelli R, Cutrona G, Vitelli G, Morabito F, Iuliano F, Foa R, Ferrarini M (2009) Increased serum BAFF (B-cell activating factor of the TNF family) level is a peculiar feature associated with familial chronic lymphocytic leukemia. Leuk Res 33(1):162–165PubMedCrossRef Molica S, Digiesi G, Mauro F, Mirabelli R, Cutrona G, Vitelli G, Morabito F, Iuliano F, Foa R, Ferrarini M (2009) Increased serum BAFF (B-cell activating factor of the TNF family) level is a peculiar feature associated with familial chronic lymphocytic leukemia. Leuk Res 33(1):162–165PubMedCrossRef
28.
Zurück zum Zitat Molica S, Digiesi G, Battaglia C, Cutrona G, Antenucci A, Molica M, Giannarelli D, Sperduti I, Gentile M, Morabito F, Ferrarini M (2010) Baff serum level predicts time to first treatment in early chronic lymphocytic leukemia. Eur J Haematol 85(4):314–320PubMedCrossRef Molica S, Digiesi G, Battaglia C, Cutrona G, Antenucci A, Molica M, Giannarelli D, Sperduti I, Gentile M, Morabito F, Ferrarini M (2010) Baff serum level predicts time to first treatment in early chronic lymphocytic leukemia. Eur J Haematol 85(4):314–320PubMedCrossRef
29.
Zurück zum Zitat Bojarska-Junak A, Hus I, Chocholska S, Wasik-Szczepanek E, Sieklucka M, Dmoszynska A, Rolinski J (2009) BAFF and APRIL expression in B-cell chronic lymphocytic leukemia: correlation with biological and clinical features. Leuk Res 33(10):1319–1327PubMedCrossRef Bojarska-Junak A, Hus I, Chocholska S, Wasik-Szczepanek E, Sieklucka M, Dmoszynska A, Rolinski J (2009) BAFF and APRIL expression in B-cell chronic lymphocytic leukemia: correlation with biological and clinical features. Leuk Res 33(10):1319–1327PubMedCrossRef
30.
Zurück zum Zitat Guadagnoli M, Kimberley FC, Phan U, Cameron K, Vink PM, Rodermond H, Eldering E, Kater AP, van Eenennaam H, Medema JP (2011) Development and characterization of APRIL antagonistic monoclonal antibodies for treatment of B-cell lymphomas. Blood 117(25):6856–6865PubMedCrossRef Guadagnoli M, Kimberley FC, Phan U, Cameron K, Vink PM, Rodermond H, Eldering E, Kater AP, van Eenennaam H, Medema JP (2011) Development and characterization of APRIL antagonistic monoclonal antibodies for treatment of B-cell lymphomas. Blood 117(25):6856–6865PubMedCrossRef
31.
Zurück zum Zitat Ansell SM, Witzig TE, Inwards DJ, Porrata LF, Ythier A, Ferrande L, Nestorov I, Devries T, Dillon SR, Hausman D, Novak AJ (2008) Phase I clinical study of atacicept in patients with relapsed and refractory B-cell non-Hodgkin’s lymphoma. Clin Cancer Res 14(4):1105–1110PubMedCrossRef Ansell SM, Witzig TE, Inwards DJ, Porrata LF, Ythier A, Ferrande L, Nestorov I, Devries T, Dillon SR, Hausman D, Novak AJ (2008) Phase I clinical study of atacicept in patients with relapsed and refractory B-cell non-Hodgkin’s lymphoma. Clin Cancer Res 14(4):1105–1110PubMedCrossRef
32.
Zurück zum Zitat Kofler DM, Gawlik BB, Elter T, Gianella-Borradori A, Wendtner CM, Hallek M (2012) Phase 1b trial of atacicept, a recombinant protein binding BLyS and APRIL, in patients with chronic lymphocytic leukemia. Leukemia 26(4):841–844PubMedCrossRef Kofler DM, Gawlik BB, Elter T, Gianella-Borradori A, Wendtner CM, Hallek M (2012) Phase 1b trial of atacicept, a recombinant protein binding BLyS and APRIL, in patients with chronic lymphocytic leukemia. Leukemia 26(4):841–844PubMedCrossRef
Metadaten
Titel
High APRIL but not BAFF serum levels are associated with poor outcome in patients with follicular lymphoma
verfasst von
Ya-Jun Li
Zhi-Ming Li
Zhong-Jun Xia
Su Li
Yi Xia
Hui-Qiang Huang
Jia-Jia Huang
Ping-Yong Yi
Wen-Qi Jiang
Publikationsdatum
01.01.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Annals of Hematology / Ausgabe 1/2015
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-014-2173-2

Weitere Artikel der Ausgabe 1/2015

Annals of Hematology 1/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.